Cognition in schizophrenia: from basic science to clinical treatment Philip D. HarveyMark A. GeyerJohn H. Krystal Introduction 30 August 2003 Pages: 213 - 214
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development John H. KrystalD. Cyril D'SouzaRalph Hoffman Review 02 September 2003 Pages: 215 - 233
Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys Gary S. LinnShobhit S. NegiDaniel C. Javitt Original Investigation 04 July 2003 Pages: 234 - 239
Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice Suzanne A. BrodyMark A. GeyerCharles H. Large Original Investigation 16 April 2003 Pages: 240 - 246
Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and α1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats T. AbekawaM. HondaT. Koyama Original Investigation 31 July 2003 Pages: 247 - 256
The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment Ina Weiner Review 25 February 2003 Pages: 257 - 297
Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia L. ZuckermanN. RimmermanI. Weiner Original Investigation 24 June 2003 Pages: 298 - 307
Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation Lee ZuckermanIna Weiner Original Investigation 14 May 2003 Pages: 308 - 313
Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm Neal R. SwerdlowNora StephanyPamela P. Auerbach Original Investigation 28 February 2003 Pages: 314 - 320
DMXB, an α7 nicotinic agonist, normalizes auditory gating in isolation-reared rats Heidi C. O'NeillKate RiegerKaren E. Stevens Original Investigation 21 May 2003 Pages: 332 - 339
Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm Angela Y. GemperleKevin H. McAllisterHans-Rudolf Olpe Original Investigation 24 June 2003 Pages: 354 - 364
Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective Wayne S. FentonEllen L. StoverThomas R. Insel Introduction 02 September 2003 Pages: 365 - 366
Right-hemisphere encephalopathy in elderly subjects with schizophrenia: evidence from neuropsychological and brain imaging studies V. S. Gabrovska-JohnsonM. ScottJ. F. W. Deakin Original Investigation 04 July 2003 Pages: 367 - 375
Cognitive rehabilitation in schizophrenia: a quantitative analysis of controlled studies Lydia KrabbendamAndré Aleman Original Investigation 24 January 2003 Pages: 376 - 382
Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications Richard S. E. KeefeMargaret P. PoeAdam Vaughan Original Investigation 21 May 2003 Pages: 383 - 389
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol Scot E. PurdonNeil WoodwardEmmanuel Stip Original Investigation 24 June 2003 Pages: 390 - 397
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia Tonmoy SharmaCatherine HughesVeena Kumari Original Investigation 04 July 2003 Pages: 398 - 403
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study Philip D. HarveyMichael F. GreenHerbert Y. Meltzer Original Investigation 18 February 2003 Pages: 404 - 411
Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning L. M. McDonaldP. M. MoranJ. A. Gray Original Investigation 09 August 2002 Pages: 321 - 331
Prepulse inhibition during withdrawal from an escalating dosage schedule of amphetamine Holger RussigCarol A. MurphyJoram Feldon Original Investigation 12 November 2002 Pages: 340 - 353
